Abstract:Vaccines are one of the most remarkable achievements in the history of medicine and the most cost-effective and efficient way to prevent infectious diseases. By stimulating the immune system, vaccines enable the body to develop a defense mechanism against pathogens. The widespread adoption of vaccines has led to the eradication of the smallpox virus and a significant reduction in the global incidence of polio, measles, and other childhood diseases. Messenger RNA (mRNA) represents an emerging class of nucleic acid therapeutics employed for the prevention and treatment of diverse diseases. mRNA vaccines involve injecting mRNA carrying the encoded antigen protein into the human body, where it functions by translating the antigen protein within cells. This process triggers the production of specific immune responses, effectively achieving the goal of immunization and prevention. During the coronavirus disease 2019 (COVID-19) pandemic, mRNA vaccines played a pivotal role, leading to an unprecedented rapid advancement in this technology. In 2023, Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their groundbreaking discovery in nucleoside modifications. These achievements underscore the immense potential of mRNA technology in the fields of life science and medical research. Although mRNA vaccines have proven to be both effective and safe in preventing infectious diseases, further research is needed to optimize mRNA design and intracellular delivery. Beyond combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), numerous mRNA vaccines are in the development pipeline for various pathogens, including influenza virus, cytomegalovirus, Zika virus, and respiratory syncytial virus infections. Furthermore, there is a burgeoning momentum in the development of mRNA vaccines and drugs for tumors and rare diseases. This review provides an overview of the characteristics of mRNA drugs and vaccines, highlighting some representative mRNA drugs or vaccines. It delves into key technologies in mRNA vaccine development, such as sequence optimization and engineering innovations. Additionally, this review also discusses advanced lipid nanoparticle delivery systems and the mechanism of action of mRNA-LNP vaccines. Finally, the authors thoroughly examine the prospects and challenges associated with mRNA vaccines.

Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems

Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era

Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems

Progress on Mrna Vaccines and Lipid Nanoparticles

A comprehensive comparison of DNA and RNA vaccines

The Coming of Age of Nucleic Acid Vaccines during COVID-19

mRNA-based modalities for infectious disease management

Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Nucleic Acid Vaccines against SARS-CoV-2

Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)

COVID-19 vaccine development and a potential nanomaterial path forward

The current landscape of nucleic acid therapeutics

Current Status and Future Perspectives on MRNA Drug Manufacturing

From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines

How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development

Delivery of nucleic acids using nanomaterials

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection